## **BIOLOGICAL ACTIONS AND TRANSLATIONAL POTENTIAL OF HYDROGEN SULFIDE**

## **Andreas Papapetropoulos**

Laboratory of Pharmacology, Faculty of Pharmacy, National and Kapodistrian University of Athens.

Over the last decade, hydrogen sulfide (H<sub>2</sub>S) has emerged as an important endogenous gasotransmitter in mammalian cells and tissues. Similar to the previously characterized gasotransmitters nitric oxide and carbon monoxide, H<sub>2</sub>S is produced by the body by enzymatic reactions and regulates a host of physiological and pathophysiological processes in various cells and tissues. H<sub>2</sub>S production and H<sub>2</sub>S tissue levels are decreased in a number of conditions (e.g. diabetes mellitus and aging) and are increased in other states (e.g. various forms of inflammation and critical illness). Over the last decades, multiple approaches have been identified for the therapeutic exploitation of H<sub>2</sub>S, either based on H<sub>2</sub>S donation or inhibition of H<sub>2</sub>S biosynthesis. H<sub>2</sub>S donation can be achieved through the inhalation of H<sub>2</sub>S gas, and/or the parenteral or enteral administration of various formulations of fast-releasing H<sub>2</sub>S donors (salts of H<sub>2</sub>S such as NaHS and Na<sub>2</sub>S), or slow-releasing H<sub>2</sub>S donors (GYY4137 being the prototypical compound). On the side of pharmacological inhibition of H<sub>2</sub>S synthesis, there are small molecule compounds targeting each of the three H<sub>2</sub>S-producing enzymes CBS, CSE and 3-MST. During the presentation, examples of the biological activities, along with translational efforts using H<sub>2</sub>S donors and H<sub>2</sub>S biosynthesis inhibitors in cardiovascular disease and cancer will be highlighted.